Information Provided By: 
Fly News Breaks for November 15, 2018
ATNX
Nov 15, 2018 | 06:53 EDT
JPMorgan analyst Leon Chik upgraded Athenex to Overweight from Neutral while lowering his price target for the shares to $15 from $24. More clinical data and progress in new drug trials should boost investor sentiment in 2019, Chik tells investors in a research note. The analyst points out that the shares have underperformed the Nasdaq composite by 40% since June as investors await Phase 3 clinical data on Oraxol, which he expects to be released by mid-2019.
News For ATNX From the Last 2 Days
There are no results for your query ATNX
